Helping you bring novel treatments for mental health to those in need.
In the United States alone, mental illnesses are among the most common health conditions, impacting an estimated 1 in 5 adults. Much is being done to remove the stigma of mental health conditions such as depression, anxiety, post-traumatic stress disorder (PTSD), and addiction. Still, the availability of treatment options for some is not suitable.
There is growing evidence from scientific studies that psychedelics could be effective treatments for a variety of mental illnesses, as well as for pain management and other diseases. Examples of psychedelic drugs that have been studied include: psilocybin, N,N-dimethyltryptamine (DMT), lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA).
Explore our drug substance and drug product capabilities:
In drug substance API manufacturing, Quotient Sciences offer a range of tailored services that can be integrated into a bespoke program, and taken forward into the development of your drug product.
Our goal is to help you bring your new treatment to market, fast.
Underpinning our drug substance development and manufacturing services is a breadth and depth of chemistry, analytical and solid-state expertise. When complimented by our expertise in oral dosage forms (OSD), nasal spray and sterile drug product development and manufacturing, Quotient Sciences offer unrivaled integrated drug development solutions to help you address the challenges associated with developing novel therapies. Contact us today to learn how we can help support the development and manufacturing needs of your next program.